Skip to main content

Table 1 Patients’ characteristics

From: The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients

Patient Characteristics Total Without event With event P
Age (years) 3.636±2.166 3.264±2.131 4.008±2.194 0.402
Gender
 Male 14(36.8%) 5(26.3%) 9(47.4%) 0.313
 Female 24(63.2%) 14(73.7%) 10(52.6%)  
Tumor primary site
 Abdomen 34(89.5%) 16(84.2%) 18(94.7%) 0.604
 Non-Abdomen 4(10.5%) 3(15.8%) 1(5.3%)  
INSS
 Stage 1 2(5.3%) 2(10.5%) 0(0.0%) 0.178
 Stage2 1(2.6%) 1(5.3%) 0(0.0%)  
 Stage3 6(15.8%) 4(21.1%) 2(10.5%)  
 Stage4 29(76.3%) 12(63.1%) 17(89.5%)  
COG
 Low risk 2(5.3%) 2(10.5%) 0(0.0%) 0.027*
 medium risk 14(36.8%) 10(52.6%) 4(21.1%)  
 high risk 22(57.9%) 7(36.9%) 15(78.9%)  
  1. INSS International Neuroblastoma Staging System, COG Children's Oncology Group, *P < 0.05